Anebulo Pharmaceuticals (NASDAQ:ANEB) Shares Down 11.1% - Should You Sell?

Key Points

• Shares of Anebulo Pharmaceuticals (NASDAQ:ANEB) fell by 11.1%, reaching a low of $2.35 during trading, with a significant decrease in volume to 217,663 shares, compared to an average of 1,152,244 shares.
• The company's stock rating was downgraded from a "strong-buy" to a "hold" by Maxim Group, impacting investor sentiment.
• Institutional investors have been active, with significant purchases and increased stakes, leading to 28.40% of the stock now owned by institutional investors, indicating potential confidence in the company despite the recent decline.

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB - Get Free Report)'s stock price traded down 11.1% during trading on Thursday . The company traded as low as $2.35 and last traded at $2.40. 217,663 shares were traded during mid-day trading, a decline of 81% from the average session volume of 1,152,244 shares. The stock had previously closed at $2.70.

Wall Street Analyst Weigh In

Separately, Maxim Group lowered shares of Anebulo Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, July 23rd.

Anebulo Pharmaceuticals Trading Down 0.4%

The stock's 50 day moving average price is $1.87 and its 200 day moving average price is $1.46. The company has a market cap of $96.95 million, a price-to-earnings ratio of -9.08 and a beta of -0.88.

Anebulo Pharmaceuticals (NASDAQ:ANEB - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.05) by $0.01. On average, equities analysts expect that Anebulo Pharmaceuticals, Inc. will post -0.52 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Anebulo Pharmaceuticals

Several institutional investors have recently bought and sold shares of ANEB. Goldman Sachs Group Inc. bought a new position in shares of Anebulo Pharmaceuticals during the first quarter worth about $62,000. Nantahala Capital Management LLC boosted its position in shares of Anebulo Pharmaceuticals by 494.1% during the 4th quarter. Nantahala Capital Management LLC now owns 3,036,325 shares of the company's stock valued at $5,101,000 after purchasing an additional 2,525,252 shares in the last quarter. Finally, 22NW LP raised its holdings in Anebulo Pharmaceuticals by 188.2% during the 4th quarter. 22NW LP now owns 15,467,300 shares of the company's stock worth $25,985,000 after buying an additional 10,101,010 shares during the period. 28.40% of the stock is currently owned by hedge funds and other institutional investors.

Anebulo Pharmaceuticals Company Profile

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.